NLS Pharmaceutics to execute 1-for-10 reverse share split
Source: SeekingAlpha
2025-10-29 06:22:55 ET
More on NLS Pharmaceutics
- NLS Pharmaceuticals receives Nasdaq approval for merger with Kadimastem
- Seeking Alpha’s Quant Rating on NLS Pharmaceutics
- Financial information for NLS Pharmaceutics
Read the full article on Seeking Alpha
For further details see:
NLS Pharmaceutics to execute 1-for-10 reverse share split
Kadimastem
NASDAQ: KMSTF
KMSTF Trading
100.0% G/L:
$5.06 Last:
1,600 Volume:
$0 Open:
KMSTF Latest News
October 29, 2025 03:53:00 am
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
September 10, 2025 06:00:00 am
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
